NCT07080879Active, not recruiting
The Advantages and Disadvantages of Linear Anastomat and Tubular Anastomat in Radical Gastrectomy of Distal Gastric Cancer
Clinical Study on the Advantages and Disadvantages of Linear Anastomat and Tubular Anastomat in Gastrointestinal Anastomosis During Radical Gastrectomy for Distal Gastric Cancer
Source: ClinicalTrials.gov · Last updated 23 Jul 2025
Brief summary (registry, in English)
The goal of this clinical trial is to observe and compare the short-term complications, long-term survival and quality of life of linear anastomat and tubular anastomat during digestive tract reconstruction after resection of distal gastric cancer. Participants will receive a linear anastomat or tubular anastomat for digestive tract reconstruction during distal gastrectomy gastroenterostomy.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- First submitted
- 9 Apr 2023
- Start date
- 1 Jun 2023
- Primary completion date
- 31 Jan 2026
- Lead sponsor
- Xiangya Hospital of Central South University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07080879
What you commit to
- Study type: Interventional
- Planned participants: 250
- From 1 Jun 2023 to the primary completion date, 31 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of upper abdominal surgery (including gastric ESD/EMR, except laparoscopic cholecystectomy);
- Gastric cancer patients who have received neoadjuvant therapy;
- Concurrent surgical treatment for other diseases is required;
- Patients with PD after neoadjuvant chemotherapy and unable to undergo distal gastrectomy;
Other illness
- History of acute pancreatitis;
- History of other malignant diseases within the past 5 years;
- History of unstable angina pectoris, myocardial infarction, cerebral infarction, or cerebral hemorrhage within the past 6 months;
- History of continuous systemic corticosteroid therapy in the past 1 month;
- Patients with gastric cancer complications (bleeding, perforation) requiring emergency surgery;
- Suffers from severe mental illness;
- Patients undergoing emergency surgery due to tumor bleeding, perforation and obstruction during chemotherapy.
Other
- Preoperative imaging examination indicated fusion of enlarged lymph nodes (maximum diameter \>3cm);
- Pyloric obstruction;
- Lung function test FEV1\< 50% of the expected value;
- Pregnant or lactating women;
- Participate in other clinical studies at the same time;
- Refused to sign the first round of study informed consent;
- Unable or unwilling to comply with research requirements;
Who the study is looking for
- Age ≤ 18 years old ≤75 years old;
- The primary gastric lesions were diagnosed as gastric adenocarcinoma (papillary adenocarcinoma pap, tubular adenocarcinoma tub, mucinous adenocarcinoma muc, sig-ring cell carcinoma, and poorly differentiated adenocarcinoma por) by gastroscopic biopsy.
- The patient was clinically diagnosed with gastric cancer (in line with clinical signs of gastrointestinal reconstruction after distal subtotal gastrectomy for gastric cancer);
- Implantation metastasis without peritoneum (confirmed by laparoscopic exploratory surgery);
- It is estimated that R0 results can be obtained after D2 radical resection of distal gastric cancer (also applicable for multiple primary lower cancers);
- Karnofsky score ≥60 points;
- Preoperative ASA score: I, II, or III; 8。 Routine blood examination (no transfusion within the past 14 days) : HB≥90g/L;ANC ≥1.5×109/L;PLT ≥80×109/L;
- 9\. Blood biochemical examination: BIL \<1.5 times the upper limit of normal value (ULN);ALT and AST\<2.5× ULN;Crea≤1 x ULN.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xiangya Hospital Central South University Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.